Zanubrutinib (Brukinsa®) is indicated as monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/10/2021|
|Rapid review completed||16/11/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.